exatecan
Small moleculeexperimental
Clinical trial activity
16 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
13
Phase 3
1
Phase 4
0
Earliest trial started Feb 1, 1999 (NCT00005091)
Timeline
Indications
Studied for
- Bile Duct Neoplasms · Phase 2
- Brain Neoplasms · Phase 1
- Breast Neoplasms · Phase 2
- Esophageal Neoplasms · Phase 2
- Fallopian Tube Neoplasms · Phase 2
- Gallbladder Neoplasms · Phase 2
- Hamartoma · Phase 2
- Leukemia · Phase 1
- Liver Neoplasms · Phase 2
- Lung Neoplasms · Phase 2
- Lymphoma · Phase 1
- Myelodysplastic Syndromes · Phase 1
- Neoplasms · Phase 1
- Ovarian Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 3
- Prostatic Neoplasms · Phase 2
- Sarcoma · Phase 2
- Stomach Neoplasms · Phase 2
- Uterine Cervical Neoplasms · Phase 2
Mechanism of action
- DNA topoisomerase II betaINHIBITOR
TOP2B inhibitor
- DNA topoisomerase IINHIBITOR
DNA topoisomerase I inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2c-1nc1cc(F)c(C)c3c1c2[C@@H](N)CC3.CS(=O)(=O)O.O.O- Mol. weight
- 567.59 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3989759 ↗
- ChEMBLCHEMBL2106563 ↗
- ChEMBLCHEMBL1614650 ↗
Also known as
- (1s,9s)-1-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-1h,12h-benzo(de)pyrano(3',4'-6,7)indolizino(1,2-b)quinoline-10,13(9h,15h)dione methanesulfonate
- dx 8951
- dx 8951
- dx-8951
- dx-8951a
- dx-8951a
- dx 8951f
- dx-8951f
- dx-8951f
- dx-8951f
- dx-8951f
- exatecan
- exatecan
- exatecan
- exatecan
- exatecan
- exatecan
- exatecan hydrochloride
- exatecan mesylate
- exatecan mesylate
- exatecan mesylate
- exatecan mesylate
- exatecan mesylate
- exatecan (mesylate)
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00055952 | Phase 2 | Jan 1, 2003 | Daiichi Sankyo |
| NCT00055939 | Phase 2 | Jan 1, 2003 | Daiichi Sankyo |
| NCT00041236 | Phase 2 | May 1, 2002 | European Organisation for Research and Treatment of Cancer, Robert Roessle Klinik |
| NCT00045318 | Phase 1 | May 1, 2002 | National Cancer Institute (NCI), University of California, Los Angeles |
| NCT00023972 | Phase 3 | Jul 1, 2001 | Daiichi Sankyo |
| NCT00017212 | Phase 2 | Apr 1, 2001 | Daiichi Sankyo |
| NCT00005938 | Phase 2 | Mar 1, 2000 | Daiichi Sankyo |
| NCT00004866 | Phase 2 | Jan 1, 2000 | Daiichi Sankyo |
| NCT00004212 | Phase 1 | Sep 1, 1999 | Daiichi Sankyo |
| NCT00004108 | Phase 2 | Sep 1, 1999 | Daiichi Sankyo |
| NCT00004060 | Phase 2 | Jul 1, 1999 | Daiichi Sankyo |
| NCT00003951 | Phase 2 | Jun 1, 1999 | Daiichi Sankyo |
| NCT00004045 | Phase 2 | Jun 1, 1999 | Daiichi Sankyo |
| NCT00004046 | Phase 2 | Jun 1, 1999 | Daiichi Sankyo |
| NCT00004047 | Phase 1 | Jun 1, 1999 | Daiichi Sankyo |
| NCT00005091 | Phase 2 | Feb 1, 1999 | Daiichi, The Christie NHS Foundation Trust |
Showing 16 of 16 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Daiichi Sankyo | For profit | 13 | 13 | 3 | 1999 |
| Daiichi | For profit | 1 | 1 | 1 | 1999 |
| European Organisation for Research and Treatment of Cancer | Academic/Hospital | 1 | 1 | 1 | 2002 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2002 |
| Robert Roessle Klinik | Academic/Hospital | 1 | 0 | 1 | 2002 |
| The Christie NHS Foundation Trust | Academic/Hospital | 1 | 0 | 1 | 1999 |
| University of California, Los Angeles | Academic/Hospital | 1 | 1 | 1 | 2002 |
7 organizations
Page 1 / 1